IGNORANT THERAPEUTIC WAYS IN HEALTH SCIENCES

##plugins.themes.academic_pro.article.main##

Shah Murad, Nusratullah Khan, Tarique Ahmed Maka, M Ismail Khoso, Saleemullah Abro, Dur Muhammad Shaikh

Abstract

Obesity and hyperlipidemia is international /worldwide problem causing heart disease leading to major predisposing factor for morbidity and death. Conventional medicine used in allopathy include statins, fibrates, niacin and resins but are going to defame due to their adverse effects. Herbal medicine ginger has proved itself as one of the potent antihyperlipidemic and antiobesity herb with least adverse effects. We did try to compare its hypolipidemic effects with placebo effects when used in mild to moderate hyperlipidemic patients. It was placebo-controlled single blind research study. Research was conducted at National hospital, Lahore, from July to November 2016. Consent was taken from sixty hyperlipidemic patients age range from 25 to 60 years. Both gender male and female patients were enrolled. Patients were randomly divided in two groups, 30 patients were on drug ginger pasted-powder advised to take 5 grams in divided doses with their normal diet for the period of three months. Thirty patients were on placebo pasted-wheat powder, with same color as of ginger powder, advised to take 5 grams in divided doses with their normal diet for the period of three months. Their base line lipid profile and body weight was recorded at start of treatment and were  advised to come for check-up, fortnightly. When duration of study was over, their lipid profile and body weight was measured and compared statistically with pre-treatment values. Three months treatment with 5 grams of ginger decreased total cholesterol from 233.11±1.53 mg/dl  to 198.44±1.23 mg/dl, LDL cholesterol reduced from 202.21±1.88 mg/dl  to 187.72± 1.98 mg/dl, reduced body weight from 76.01±2.66 kg  to 72.80±1.87 kg. Both plasma total cholesterol and LDL cholesterol reduction was statistically significant, but body weight decrease was non-significant when analyzed biostatistically.

##plugins.themes.academic_pro.article.details##

Author Biography

Shah Murad, Nusratullah Khan, Tarique Ahmed Maka, M Ismail Khoso, Saleemullah Abro, Dur Muhammad Shaikh

 Professor and HOD, Pharmacology,  DANTH/SZABMU/IMDC, Islamabad, Pakistan.

Assistant Prof of Biochemistry at Bolan University of Medical and health Sciences, Quetta, Pakistan

ENT Specialist at CMH Mangla, Pakistan

Consultant Physician at CMH Mangla, Pakistan

Assistant Professor of Physiology, Baqai Medical University, Karachi Pakistan

Microbiology Department at JSMU Karachi Pakistan

How to Cite
Shah Murad, Nusratullah Khan, Tarique Ahmed Maka, M Ismail Khoso, Saleemullah Abro, Dur Muhammad Shaikh. (2020). IGNORANT THERAPEUTIC WAYS IN HEALTH SCIENCES. International Journal of Medical Science in Clinical Research and Review, 3(02 ,), Page: 40–44. Retrieved from http://ijmscrr.in/index.php/ijmscrr/article/view/77

References

    1. McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 2014;81:60B-5.

    2. Weiss SR, Davidson MH, Sprecher L, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 2015; 15:678-82.

    3. Torre-Amione G. CAD; new slant on the disease. Drug Saf. 2010;23:197-213.

    4. Srivastava A, Sharma SK, Gupta YK. Hyperlipidemia: Consideration point about coronary artery disease. J Ethnopharmacol. 2012;140:151-60.

    5. Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2016;55:39-44.

    6. Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet. 2015;353:1274.

    7. P. Victoratos, N, Perulis, N. Stefanou, M. Jiangou, L. Hadjipetrou, P.N.Kourounakis. Experimental hyperlipidemia and the effect of statins . Experimental and Molecular Pathology. 2012:73:135-38.

    8. Blair SN. AHA Guidelines for primary prevention of cardiovascular disease and stroke. American Heart association Science Advisory and Coordinating Committee. Circulation 2012; 106:388-91.

    9. Finaldave YT, Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Zingiber officinale is potent hypolipidemic herb? Circulation. 2014;100:96-102.

    10. Phhondah C, Zaoui, A., Cherrah, Y. et al. Diuretic, hypolipidemic and hypotensive effects of Zingiber O. Therapie Herb Med 2015;55(3): 379-90.

    11. YT Lemakapesa , PE Schurr. Triton – induced hyperlipidemia in rats as an animal model for screening hyperlipidemic drugs. Ir J Lipids. 2015;6:3-9.

    12. Ting-Wei Lan, I-Min Liu, Shorong-Shii Liou, Feng-Lin Hsu, Juei-Tang Cheng. Herbal medicines are good for cardiac health. Planta Med. 2014:7(5): 617-18.

    13. Loompera, Maderchudh, Kahlon. In vitro binding of bile acids by okra, beets, Ginger, asparagus, eggplant, turnips, green beans, carrots, and cauliflower. Food chemistry. 2015:103 (2): 122-30.

    14. Macdophas EM, El-Dakhakhny M. Studies on chemical constitution of ginger and its effects. Planta Med 2015;2:1465-6.

    15. Tulip K, Siryt F, Ramadan M.F. Nutritional value, functional properties and nutraceutical applications of Ginger O. Int. J. Food Sci. Tech. 2013; 41: 1208-11.

    16. SK Ashraf, Noor Mohammad, Mohammad Qasim, Mohd. Anwar Buriro et al; Contents and effects of ginger on lipid profile in hyperlipidemic patients. Gomal Journal of Medical Sciences 2014;5; 3; 1215-21.

    17. Phanotavel GM, Knowler WC, Barrett Connor E, Fowler SE et al. Zingiber O oil preparation for plasma lipid lowering effects. J Her Med 2012; 346(6):401-6.

    18. Sumaira A, Zahida T., Zeshan S, Nisar A and Mushtaq H.L. The Effects of oil preparation of Ginger and its effects on hyperlipidemia. Pakistan Journal of Nutrition 2012;10:162-3.

    19. Ashok K, Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome and its treatment by Zingiber officinale. Diabetes Res Clin Pract. 2014;60:199-204.

    20. Kasaveyun PS, Le P.M., A. Benhaddou-Andaloussi, A. Settaf, Y. Cherrahand P.S. Haddad. Zingiber O extract used as CAD preventive medicinal herb. J. Ethanopharmacol. 2014;94:251-59.

    21. Sitavan C, Pakoorama T, Mustave X, Khaw K. Zingiber Officinale can reduce plasma lipids and body weight significantly. Circulation 2015; 69:1065-9.

    22. Cokava VI, Ponasam KT, Verma, SK., and Srivastava, K. C. Effect of ginger on blood lipids, and body weight. J Met Dis 2015;56(5):379-84.

    23. Johsin PT, Viana RM, Schimith MA. Ginger act as free radical scavenger herb. Arq Bras Cardiol 2013; 72: 569-74.

    24. Fujar LM, Janssen PL., Meyboom, S., van Staveren, W. A., de Vegt, F., and Katan, M. B. Consumption of ginger in hyperlipidemic female patients in close supervision and counseling. Eur J Clin Nutr 2015;50(11):772-74.

    25. Illasi J, Jusamnuy F, Mucao V, Sundaw F, Faraso S. Moderately potent hypolipidemic herb: Zingiber Officinale. N Engl J Med 2015;339:1349-57.

    26. Solerka YT, Makasidve AE Moriguchi EH, Forsek L. Metabolic syndrome and its treatment by herbal medication. J Cl Nut 2015;3:9-14.

    27. Domerluve L, Finher C Munawe L, Saqore G. Effect of onion and ginger consumption on platelet thromboxane production in humans. J Diab 2016;35(3):183-85.

    28. Kulmharree C, Savage J, Gunaqa U, Farrawe D. Three months are required to treat secondary hyperlipidemia by herbal medicine. Ethop J Med Sc 2014;10:3-7.

    29. Dosaka BV, Shryock AM, Oblesby P. Atherogenesis and hyperlipidemia can be prevented by herbs. Pak J Med 2014;304:65-70.

    30. Jalebii VC, Molker CT, Vogerc BB, Posterr JU. Ginger extracts utilization in metabolic syndrome. JMP 2015;12(7):444-50.

    31. Jimeeshergi GT, Volker PB, Metalove ST, Filkker CR. Phytochemicals as alternative therapies. LJI 2013;3(1):90-3.